Patents by Inventor Elke Jäger

Elke Jäger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR THE TREATMENT OF A TUMOR PATIENT WITH ADOPTIVE T CELL IMMUNOTHERAPY
    Publication number: 20210169937
    Abstract: The present invention relates to a method of treating a tumor disease, comprising one or more administrations of a T cell product, a T cell product for use in a method of treating a tumor disease, as well as a kit for use in a method of treating a tumor disease.
    Type: Application
    Filed: July 26, 2019
    Publication date: June 10, 2021
    Applicant: NORDWEST POLYBIOCEPT BIOSCIENCE GMBH
    Inventors: Ernest DODOO, Elke JÄGER, Julia KARBACH, Markus MAURER
  • Combination therapy including tumor associated antigen binding antibodies
    Publication number: 20180353603
    Abstract: The present invention relates to a combination therapy including tumor associated antigen binding antibodies.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Inventors: Christoph Esslinger, Alexander Knuth, Martin Treder, Maries van den Broek, Elke Jaeger
  • MAGEA3 BINDING ANTIBODIES
    Publication number: 20140186363
    Abstract: The present invention relates to MAGEA3 binding antibodies.
    Type: Application
    Filed: May 23, 2012
    Publication date: July 3, 2014
    Applicants: UNIVERSITY OF ZURICH, CT ATLANTIC LTD.
    Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jaeger
  • MAGEA3 BINDING ANTIBODIES
    Publication number: 20140093514
    Abstract: The present invention relates to MAGEA3 binding antibodies.
    Type: Application
    Filed: May 23, 2012
    Publication date: April 3, 2014
    Applicants: University of Zurich, CT ATLANTIC LTD.
    Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jäger
  • COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTIGEN BINDING ANTIBODIES
    Publication number: 20130295091
    Abstract: The present invention relates to a combination therapy including tumor associated antigen binding antibodies.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 7, 2013
    Applicants: University of Zurich, CT ATLANTIC LTD
    Inventors: Christoph Esslinger, Alexander Knuth, Martin Treder, Maries Van Den Broek, Elke Jaeger
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8541202
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: September 24, 2013
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN
    Publication number: 20120231035
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 13, 2012
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8142786
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 27, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Publication number: 20110182944
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 28, 2011
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
    Patent number: 7888100
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 15, 2011
    Assignees: Memorial Sloan-Kettering Cancer Research, Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof
    Patent number: 7291335
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: November 6, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Elisabeth Stockert, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Alexander Knuth, Lloyd J. Old
  • Methods for detection of disease-associated antibodies in urine
    Patent number: 7125681
    Abstract: The present invention provides methods and diagnostic kits for the detection of disease-specific antibodies in urine containing sample. The present invention is also directed toward methods for determining that a patient suffers from a disorder characterized by aberrant expression of a naturally occurring gene. Methods for monitoring the status of a disorder in a patient characterized by aberrant expression of a naturally occurring gene are also provided.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: October 24, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Dirk Jäger
  • Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53
    Patent number: 7115729
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: January 2, 2004
    Date of Patent: October 3, 2006
    Assignees: Cornell Research Foundation, Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
    Patent number: 6723832
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: April 20, 2004
    Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, Academisch Ziekenhuis Leiden, Cornell Research Foundation
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
    Patent number: 6576756
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: June 10, 2003
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc., Memorial Sloan-Kettering Cancer Center
    Inventors: Yao-Tseng Chen, Ali Gure, Solam Tsang, Elisabeth Stockert, Elke Jäger, Knuth Alexander, Lloyd J. Old
  • Truncated forms of NY-ESO-1 protein
    Patent number: 6525177
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: February 25, 2003
    Assignees: Cornell Research Foundation, Inc., Ludwig Institute for Cancer Research, Sloan-Kettering Cancer Center
    Inventors: Elisabeth Stockert, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Knuth Alexander, Lloyd J. Old
  • Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
    Patent number: 6297364
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: October 2, 2001
    Assignees: Ludwig Institute For Cancer Research, Cornell Research Foundation, Inc., Memorial Sloan-Kettering Cancer Center
    Inventors: Yao-Tseng Chen, Ali Gure, Solam Tsang, Elisabeth Stockert, Elke Jäger, Knuth Alexander, Lloyd J. Old
  • Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
    Patent number: 6274145
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: August 14, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yao-tseng Chen, Matthew Scanlan, Ali Guré, Lloyd J. Old, Elke Jäger, Knuth Alexander, Jan W. Drijfhout, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
    Patent number: 6251603
    Abstract: The invention relates to methods for determining tumor status by determining antibodies specific to NY-ESO-1 in patient samples. One can determine whether a cancerous condition is progressing, regressing, or remaining stable by determining antibodies against NY-ESO-1 in a patient sample, and comparing the value obtained to a prior value. When the tumor in question expresses NY-ESO-1, a change in this value is indicative of a change in status of the cancerous condition.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: June 26, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Elke Jäger, Elisabeth Stockert, Lloyd J. Old, Alexander Knuth
  • Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
    Patent number: 6252052
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: June 26, 2001
    Assignees: Cornell Research Foundation, Inc, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center
    Inventors: Elisabeth Stockert, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Knuth Alexander, Lloyd J. Old